Novel Drug Candidates for the Treatment of Cardiac and Renal Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 1377
Special Issue Editors
Interests: mitochondrial dysfunction; inflammation; bioenergetics, cardiac diseases; renal diseases; treatments; antioxidants
Interests: mitochondria; reactive oxygen species; antioxidants; renal diseases; cardiac diseases
Special Issues, Collections and Topics in MDPI journals
Interests: renal diseases; diabetes; metabolic syndrome; oxidative stress; antioxidants
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Kidney diseases are a growing health problem worldwide that can lead to the development of cardiac alterations, causing millions of deaths. Renal and cardiac diseases are intrinsically related through the pathology known as cardiorenal syndrome (CRS), which consists of acute or chronic failure of the kidney or heart that leads to dysfunction of the other organ. Thus, five subtypes of CRS are highly prevalent due to the global prevalence of heart and renal pathologies. Recent research has advanced our understanding of CRS, and factors such as redox alterations, oxidative stress, inflammation, dyslipidemia and fibrosis are recognized as potential triggers of this pathology. However, specific therapies are not yet available for clinical routine.
Therefore, we welcome submissions to our Special Issue entitled “Novel Drug Candidates for the Treatment of Cardiac and Renal Diseases”. Manuscripts focusing on novel treatments for renal and/or cardiac diseases are welcome to further advance our understanding in this area.
Dr. Ana Karina Aranda-Rivera
Prof. Dr. José Pedraza Chaverri
Dr. Diana Barrera-Oviedo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kidney diseases
- cardiac diseases
- cardiorenal syndrome
- treatments
- chronic kidney diseases
- drugs
- dyslipidemia
- oxidative stress
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
